BIOP -- BioPulse Announces Major Breakthrough in Treatment of Solid Tumors
November 28, 2000 05:00
BioPulse Announces Major Breakthrough in Treatment of Solid Tumors
Jump to first matched term
Patent Pending Product is First to Show Tumor Liquefaction in Human Trials
SAN YSIDRO, Calif., Nov. 28 /PRNewswire/ -- BioPulse International, Inc. (OTC Bulletin Board: BIOP) today announced what it believes is a major breakthrough in the treatment of solid tumors using a new mixture of anti-cancer cytokines. Cytokines are powerful chemical substances secreted by cells. For cancer treatment, the best known cytokines are interleukin-2 and types of interferon, both of which are approved for human use by the FDA. The new BioPulse cytokine mixture, for which a patent is pending, uses a unique combination of a full spectrum of cytokines to enhance the ability of tumor necrosis factor (TNF) to destroy tumors.
BioPulse president Loran Swensen explained, "Our new cytokine mixture offers the potential to significantly expand the clinical trial options available for cancer patients. The product contains tumor necrosis factor TNF, and the specific mixture appears to overcome the problems that other companies have had in working with TNF. Early clinical trials have shown that in some individuals, our cytokine product results in rapid liquefaction of solid tumors." Swensen added, "Other companies in previous clinical trials, in some cases, have been able to accomplish liquefaction of tumors using TNF, but only in other species. Clinical trials of TNF in humans were disappointing because tumor cells secrete TNF-blocking agents. The new cytokine mixture appears to overwhelm these blocking agents. BioPulse is the first company to achieve these results in humans."
About BioPulse:
This fast growing, profitable, San Diego based Biotech company is combining alternative and biotech treatments for cancer and other diseases. The company owns a compelling portfolio of proprietary therapeutics and diagnostics, as well as clinics, which offer a comprehensive array of state of the art procedures.
Various statements made within this press release may constitute "forward-looking statements" for purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectations.
CONTACT: John Liviakis of Liviakis Financial Communications Inc., 415-389-4670, or fax, 415-389-4694, or moreinfo@lfcnet.com, for BioPulse International, Inc.
SOURCE BioPulse International Inc.
/CONTACT: John Liviakis of Liviakis Financial Communications Inc.,
415-389-4670, or fax, 415-389-4694, or moreinfo@lfcnet.com, for BioPulse
International, Inc./
/Web site: www.biopulse.com/
(BIOP) |
